Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...
Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
Zydus has launched Tishtha, an affordable biosimilar of nivolumab, at nearly one-fourth the original price. Approved by the ...
Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...
The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...
India Today on MSN
Zydus launches blockbuster cancer drug at a fraction of cost
As cancer cases climb steadily across India, lower-cost biosimilars like Tishtha could reshape access to life-saving immunotherapy.
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line ...
“Tecvayli Treatment Combo Improves Outcomes in Relapsed/Refractory Myeloma,” CURE; ...
DelveInsight's PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results